299660 — Cellid Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩52bn
- KR₩49bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 909 | 480 | 0 |
Cost of Revenue | |||||
Gross Profit | 0 | 0 | 909 | 155 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 3,531 | 5,287 | 13,920 | 15,391 | 11,904 |
Operating Profit | -3,531 | -5,287 | -13,011 | -14,911 | -11,904 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2,494 | -4,126 | -13,071 | -22,865 | -11,611 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2,494 | -4,126 | -13,071 | -22,865 | -11,611 |
Net Income Before Extraordinary Items | |||||
Net Income | -2,494 | -4,126 | -13,071 | -22,865 | -11,611 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -2,494 | -4,126 | -13,071 | -22,865 | -11,611 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -232 | -374 | -1,176 | -2,052 | -1,105 |
Dividends per Share |